University of Michigan (U-M) spinout company Courage Therapeutics has received a seed investment of up to $7.8 million from Arsenal Bridge Ventures. The investment will enable Courage Therapeutics to complete essential testing and development to advance its drug candidates to clinical trials. The company’s two… Read More
A drug discovery company co-founded by researchers at the University of Dundee and the University of Arizona has received $4 million in venture funding. Branch Therapeutics, founded in November 2024, is a preclinical stage company seeking to develop drugs that are orally bioavailable, well-tolerated, and can treat… Read More
Enedra Therapeutics has secured venture financing and non-dilutive funding through UKRI’s Innovate UK Future Economy Investor Partnerships programme to support the development of next-generation precision therapies for advanced, genetically heterogeneous cancers. The financing round was supported by KU Leuven’s Centre for Drug Design and Discovery (CD3), o2h… Read More
Basel Area Business & Innovation has relaunched its DayOne Accelerator, a programme dedicated to international early stage healthtech ventures looking to engage with the pharma industry. The Accelerator is based in Basel, Switzerland – a leading life sciences hub, home to pharma giants like Novartis and Roche. … Read More
A new start-up aimed at discovering and developing anti-inflammatory disease medicines has been formed by The University of Queensland’s commercialisation arm UniQuest and global biotech company Molecule to Medicine (MTM). Curlew Bio will leverage expertise from the Queensland Emory and Drug Discovery Initiative (QEDDI) and research developed… Read More
TRIMTECH Therapeutics, a biotech company harnessing targeted protein degradation (TPD) for the treatment of neurodegenerative diseases, has closed a $31 million seed funding round. The investment will support further development of the company’s pipeline of central nervous system (CNS) penetrant therapeutics based on its aggregate-selective degrader molecules… Read More
Biotechnology company Callio Therapeutics has announced its launch with the closing of a $187 million Series A financing round. Callio is focused on realising the promise of multi-payload antibody-drug conjugates (ADCs) to improve cancer therapy. The newly formed company, with headquarters in Seattle and Singapore,… Read More
DDW Editor Reece Armstrong speaks to Dr Carina Kern, Chief Executive Officer and Chief Scientific Officer, and Serena Kern-Libera, Chief Operating Officer, at LinkGevity about the company’s approach to tackling age-related diseases. RA: Could you tell us about LinkGevity’s approach to developing broad-spectrum therapeutics in the field of ageing? … Read More
Akribion Therapeutics has exited stealth mode and completed a seed financing round, raising €8 million to accelerate the development of novel therapeutics. The round was led by CARMA FUND and RV Invest, with investments from MP Beteiligungs, Hessen Kapital I, Bruker Invest and High-Tech Gründerfonds. … Read More
Research funded by the UK’s Medical Research Council (MRC) has led to spin-out companies with an economic value of greater than £6.1 ($7.5) billion, according to a new report. The report looked at the 206 spin-outs for which there was Pitchbook data. These companies accounted for around… Read More
Windward Bio, a clinical-stage, drug development company focused on advanced immunological diseases, has announced its official launch. OrbiMed, Novo Holdings, and Blue Owl Healthcare Opportunities lead the Series A financing of $200 million, with the co-investment of SR One, Omega Funds, RTW Investments, Qiming Venture Partners, Quan… Read More
Sentinal4D, a spinout company from The Institute of Cancer Research (ICR), London, has been announced to the public after closing its first round of funding. The new company aims to accelerate drug discovery and development to target drugs to patients, using patented artificial intelligence-driven methods for personalised… Read More
Orakl Oncology has announced an €11 million seed funding round, led by Singular, with support from Bpifrance including the Grand Prix i-Lab, and participation from existing investors. The new funding will be used to accelerate the company’s growth and support the launch of two new commercial products,… Read More
Start-up Starget Pharma has raised $5.1 million in funding to support development of its radioligand-based therapies that target tumour cells with focused radiation. The investment was secured from Cancer Focus, a fund established in collaboration with the MD Anderson Cancer Center at the University of Texas. Read More
Dr Christine Allen, Co-Founder and CEO of Intrepid Labs tells Lu Rahman why the company’s technology has the ability to streamline the drug development process and improve the success rate of getting drugs to market. Intrepid Labs is the first spin-off from the University of Toronto’s Acceleration Consortium, which received… Read More
A group of former Pfizer employees have created their own businesses based at and supported by Discovery Park, a life sciences community in Kent, UK. The new businesses are all contract research organisations (CROs), namely Biowaived, Matheus Engineering and Particology. Their launch has been supported by… Read More
